Skip to main content
Journal cover image

Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11)

Publication ,  Conference
Desjardins, A; Barboriak, D; Herndon, JE; Reardon, D; Quinn, J; Rich, J; Sathornsumetee, S; Friedman, H; Vredenburgh, J
Published in: NEURO-ONCOLOGY
October 1, 2007

Duke Scholars

Published In

NEURO-ONCOLOGY

ISSN

1522-8517

Publication Date

October 1, 2007

Volume

9

Issue

4

Start / End Page

573 / 574

Location

Dallas, TX

Publisher

DUKE UNIV PRESS

Conference Name

12th Annual Meeting of the Society-for-Neuro-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Barboriak, D., Herndon, J. E., Reardon, D., Quinn, J., Rich, J., … Vredenburgh, J. (2007). Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11). In NEURO-ONCOLOGY (Vol. 9, pp. 573–574). Dallas, TX: DUKE UNIV PRESS.
Desjardins, Annick, Daniel Barboriak, James E. Herndon, David Reardon, Jennifer Quinn, Jeremy Rich, Sith Sathornsumetee, Henry Friedman, and James Vredenburgh. “Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11).” In NEURO-ONCOLOGY, 9:573–74. DUKE UNIV PRESS, 2007.
Desjardins A, Barboriak D, Herndon JE, Reardon D, Quinn J, Rich J, et al. Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11). In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2007. p. 573–4.
Desjardins A, Barboriak D, Herndon JE, Reardon D, Quinn J, Rich J, Sathornsumetee S, Friedman H, Vredenburgh J. Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11). NEURO-ONCOLOGY. DUKE UNIV PRESS; 2007. p. 573–574.
Journal cover image

Published In

NEURO-ONCOLOGY

ISSN

1522-8517

Publication Date

October 1, 2007

Volume

9

Issue

4

Start / End Page

573 / 574

Location

Dallas, TX

Publisher

DUKE UNIV PRESS

Conference Name

12th Annual Meeting of the Society-for-Neuro-Oncology

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences